1.
Indian J Dermatol Venereol Leprol
;
2012 Sept-Oct; 78(5): 632-634
Article
Dans Anglais
| IMSEAR
| ID: sea-141179
Résumé
Pemphigus is a potentially fatal autoimmune epidermal bullous disorder. Rituximab is a novel therapy for the treatment of refractory pemphigus. However, there is limited clinical data on safety and efficacy of rituximab in pediatric age group. Herein, we report an 11-year-old boy of childhood pemphigus vulgaris who failed to respond to dexamethasone pulse therapy and was subsequently treated with rituximab and achieved complete remission.